

Detailed Agenda

Day 1: October 19

9:30 – 10:00 | **Opening Session** Connecting Science, Innovation, and Global Health to Confront Viral Threats



Prof. Patrick Rampal
GVN Center Director
President, Centre Scientifique de Monaco



Dr. Christian Bréchet
GVN President
University of South Florida



Dr. Robert Gallo
GVN Co-Founder
Institute of Human Virology



Mathew L. Evins
Executive Chairman & Treasurer
GVN Board of Directors

10:00 – 11:30 | **Scientific Session** Harnessing AI to Transform Pandemic Preparedness



Dr. John Lees
European Bioinformatics Institute
“The benefits of data sharing and artificial intelligence for viral research”



Dr. Marcel Salathé
Swiss Federal Institute of Technology in Lausanne
“Is the future of public health technology AI, or privacy?”



Dr. Richard Scheuermann (Session Chair)
GVN Center Director
National Library of Medicine, U.S. National Institutes of Health
“Exploring the cellular pathology of the COVID-19 lung using single cell genomics and artificial intelligence”

14:30 – 18:30 | **Joint CSM/GVN Session** Advancing Pandemic Preparedness across Countries - Under the Presidency of Prince Albert II



Prof. Patrick Rampal
GVN Center Director
President, Centre Scientifique de Monaco
“Remembering Prince Rainier III”



Dr. Hans Kluge
WHO Europe
“Collaborative surveillance network for pathogen surveillance across Europe”



Dr. Richard Pebody
WHO Europe
“Epidemic and pandemic prone viral pathogens - what surveillance do we need?”



Dr. Jean-Paul Gonzalez
Georgetown University Medical School
“Global Biomonitoring of Virus Emergence and Geographic Spread”



Dr. Linfa Wang
GVN Center Director
Duke-NUS Medical School
“Pathogen surveillance: from Singapore to the region and the world”



Dr. Marion Koopmans
GVN Center Director
Erasmus MC Department of Viroscience
“Integrating big data, metagenomics and citizen science for emerging disease surveillance”



Dr. Johan Neyts
GVN Center Director
Rega Institute for Medical Research,
University of Leuven
“Broader-spectrum antivirals for epidemic and pandemic preparedness”



Dr. Anders Vahlne
GVN Center Director
GVN Board Member
Karolinska Institutet
“Going for SARS-CoV-2 herd immunity. The Swedish experiment”



Dr. Pascal Barbry
French National Center for Scientific Research
“Monitoring respiratory pathogens by wastewater nanopore sequencing”

Roundtable Discussion

Dr. Christian Bréchet, Dr. Marion Koopmans, Dr. Johan Neyts, Dr. Linfa Wang, Dr. Anders Vahlne

Day 2: October 20

9:00 – 10:40 | **Scientific Session** Exploring the Host-Virus Relationship in Acute and Post-Acute SARS-CoV-2 Infection



Dr. Rubeshan Perumal
GVN Member
Centre for the AIDS Programme of Research in South Africa
“Long COVID – an update on the work the GVN LC Taskforce and the path ahead.”



Dr. Diane Griffin
GVN Center Director
Johns Hopkins Bloomberg School of Public Health
“What can measles teach us about COVID-19?”



Dr. Susan Weiss
Perelman School of Medicine at the University of Pennsylvania
“Interferon responses in the nasal epithelium distinguish lethal coronaviruses from common coronaviruses and are critical for viral clearance”



Dr. Thomas Althaus (Session Chair)
GVN Member
Monaco Directorate of Health
“The Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination and Infection on Neutralizing Antibodies: A Nation-wide Cross-sectional Analysis”



Dr. Eric Voiglio
Monaco Directorate of Health
“How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021–September 2022”


11:10 – 12:30 | **Scientific Session** Taking the Lead: GVN's Initiative in Tackling the Challenges of Arboviruses and Hemorrhagic Fever Viruses



Dr. Christine Carrington (Session Chair)
GVN Center Director
University of the West Indies, St. Augustine
“Arboviruses in Trinidad and Tobago – Past, Present, Future”



Dr. Robert Garry
GVN Center Director
Tulane University
“Lassa Fever: Progress and Promise”



Dr. Scott Weaver
GVN Center Director
University of Texas Medical Branch
“Effect of Heterologous Flavivirus Immunity on Urban Yellow Fever Emergence Potential”




Dr. Amadou Sall
GVN Center Director
Institut Pasteur de Dakar

14:30 – 16:10 | Scientific Session

Anticipating and Responding to Emerging Viruses:
What We Do Well and What We Need to Do Better



Dr. Ab Osterhaus (Session Chair)
GVN Center Director
The Research Center for Emerging Infections and Zoonoses
“A History of Pandemics: Can we do better next time?”



Dr. Meghan Vermillion
GVN CPP Member
Gilead
“Remdesivir and obeldesivir as broad-spectrum antiviral agents for pandemic and emerging viruses”



Dr. Osbourne Quaye
GVN Center Director
University of Ghana
“Potential Emerging Viruses Through Spillover Activities; Understanding Persistence and Dynamics of RNA Viruses in Bats in Ghana”



Dr. Sarah Londrigan
GVN Member
Peter Doherty Institute for Infection and Immunity
“Identification of novel host proteins that are associated with macrophage control of influenza A virus replication.”



Dr. Jonathan Ewbank
European Research Infrastructure on Highly Pathogenic Agents
“ERINHA’s contribution to pandemic preparedness, in Europe and beyond”

16:30 – 17:50 | Scientific Session Oncogenic Viruses: New Understandings



Dr. William Hall (Session Chair)
GVN Center Director
GVN Board Member
GVN Co-Founder
University College Dublin



Dr. Abelardo Araújo
GVN Center Director
The Federal University of Rio de Janeiro
“HTLV-1 Associated Neurological Complex. What is Hidden below the Water?”



Dr. Masao Matsuoka
GVN Member
Kumamoto University
“How HTLV-1 causes diseases in humans”



Dr. Eduardo Gotuzzo
GVN Center Director
Universidad Peruana Cayetano Heredia
“The malignancy diseases in HTLV Peruvian cohort”



Dr. Joakim Dillner
GVN Member
Karolinska Institutet
“Human Papillomavirus infection: The scientific basis for global elimination efforts.”

Day 3: October 21

9:00 – 11:00 | **Scientific Session** Advancing Antiviral Diagnostics & Treatment Through Innovation



Dr. Raymond Schinazi
GVN Center Director, GVN Board Member
Emory University
“Novel nucleoside analogs for SARS-CoV-2 infections”



Dr. Erica Ollmann Saphire
GVN Center Director
La Jolla Institute for Immunology
“Antibodies against Global Infectious Disease”



Dr. Johan Neyts
GVN Center Director
Rega Institute for Medical Research,
University of Leuven
“The AntiVirome, new druggable targets in the replication cycle of viruses”



Dr. Sharon Lewin (Session Chair)
GVN Center Director
Peter Doherty Institute for Infection and Immunity
“New platform approaches to develop direct acting antivirals at speed: the role of RNA targeting strategies”



Dr. Sara Javornik Cregeen
Baylor College of Medicine
“Comprehensive Wastewater Sequencing Reveals Community and Variant Dynamics of the Collective Human Virome”



Dr. Al Ozonoff
Broad Institute
“Surveillance of viral pathogens using CRISPR-based detection assays”

11:30 – 13:00 | **The Vision of GVN** GVN Strategic Plan 2023-2028



Dr. Christian Bréchet
GVN President
University of South Florida



Mathew L. Evins
Executive Chairman & Treasurer
GVN Board of Directors



Dr. Brett Giroir
GVN Board Member



Dr. Sten Vermund
GVN President-Elect

**Thank you for participating in the
GVN Annual Scientific Meeting in Monaco!**

Meeting Media Contact:
Nora Samaranayake
nsamaranayake@gvn.org